Publications by authors named "Rashit Bogdanov"
Introduction: Anti-T-lymphocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy) prevent graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT), yet individual patients benefit differentially.
Methods: Given the sparse comparative data on the impact of cellular immune reconstitution in this setting, we studied flow cytometry and clinical outcomes in 339 recipients of 10/10 matched-unrelated donor (MUD) HCT using either ATG (n=304) or PTCy (n=35) for T cell manipulation along with a haploidentical PTCy control cohort (n=45). Longitudinal cellular immune reconstitution data were analyzed conventionally and with a data science approach using clustering with dynamic time warping to determine the similarity between time-series of T cell subsets.
Article Synopsis
- - The study found that including mutation status enhances risk assessment for newly diagnosed chronic myelomonocytic leukemia (CMML) patients, aiding in patient selection for stem cell transplantation.
- - Specifically, mutations in ASXL1 and NRAS were linked to worse survival post-transplant, and a new prognostic score was developed to categorize risk based on these mutations and other clinical factors.
- - This CMML transplant score effectively predicts survival and non-relapse mortality, assigning scores based on genetic indicators and comorbidities, thereby outperforming previous scores and aiding in personalized treatment strategies.
Even in the era of PCR-based monitoring, prophylaxis, and preemptive therapy, Cytomegalovirus (CMV) viremia remains a relevant cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT). However, studies using binary analysis (presence/absence of CMV) reported contradicting data for NRM, overall survival and leukemia relapse. Here, we analyzed CMV replication kinetics in 11 508 whole blood PCR samples of 705 patients with HCT between 2012 and 2017.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to assess the effectiveness of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with chronic myelomonocytic leukemia (CMML) aged 70 or younger, comparing 119 patients who received the treatment to 142 who did not.
- *Results indicated that higher-risk patients (based on the CMML-specific prognostic scoring system) showed improved survival rates post-transplantation, with a 37% reduction in death risk.
- *The findings suggest allo-HCT could be beneficial for higher-risk CMML patients, but there is a need for a better risk assessment approach for transplantation outcomes, emphasizing the necessity for larger, prospective studies.*
Interleukin-18 (IL-18) is an immunoregulatory cytokine and a context-dependent regulator of hematopoietic stem/progenitor cell (HSPC) quiescence in murine models. In a previous study, high pre-conditioning levels of IL-18 were associated with increased non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). To investigate the clinical impact of IL-18 status on hematopoietic function, the associations of pre-conditioning and day 0-3 cytokine levels with platelet and neutrophil recovery were analyzed in a training cohort of 714 allografted patients.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis is a blood disease where people can have mutations in certain genes, and studying these mutations helps doctors decide on treatments.
- This study looked at 18 patients with myelofibrosis who had a special type of transplant done in four different hospitals.
- The results showed that patients who had mutations in the MPL gene did really well after the transplant, with very few relapsing into the disease.
Article Synopsis
- * A new prognostic scoring system called the myelofibrosis transplant scoring system (MTSS) was developed using data from 361 patients, identifying factors like age, health status, and genetic mutations that influence survival rates post-transplant.
- * The MTSS categorizes patients into four risk levels based on their scores, showing significant differences in 5-year survival rates among these groups while outperforming existing prognostic models.